

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problems Mailbox.**



PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :	A2	(11) International Publication Number: WO 99/67417
C12Q 1/00		(43) International Publication Date: 29 December 1999 (29.12.99)

(21) International Application Number: PCT/US99/14119	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 23 June 1999 (23.06.99)	
(30) Priority Data: 60/090,393 23 June 1998 (23.06.98) US	
(71) Applicant (for all designated States except US): THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES [US/US]; National Institutes of Health, Office of Technology Transfer, Suite 325, 6011 Executive Boulevard, Rockville, MD 20852 (US).	
(72) Inventors; and	
(75) Inventors/Applicants (for US only): ERICKSON, John, W. [US/US]; 5406 Jefferson Boulevard, Frederick, MD 21703 (US). GULNIK, Sergei, V. [US/US]; 8004 Meadowview Drive, Frederick, MD 21702 (US).	
(74) Agents: GAGALA, Bruce, M. et al.; Leydig, Voit & Mayer, Ltd., Suite 4900, Two Prudential Plaza, 180 North Stetson, Chicago, IL 60601-6780 (US).	

(54) Title: FITNESS ASSAY AND ASSOCIATED METHODS



(57) Abstract

The present invention provides an assay for determining the biochemical fitness of a biochemical species in a mutant replicating biological entity relative to its predecessor. The present invention further provides a continuous fluorogenic assay for measuring the anti-HIV protease activity of protease inhibitor. The present invention also provides a method of administering a therapeutic compound that reduces the chances of the emergence of drug resistance in therapy. The present invention also provides a compound of formula (I) or a pharmaceutically acceptable salt, a prodrug, a composition, or an ester thereof, wherein A is a group of formulas (A), (B), (C) or (D); R¹, R², R³, R⁵ or R⁶ is H, or an optionally substituted and/or heteroatom-bearing alkyl, alkenyl, alkynyl, or cyclic group; Y and/or Z are CH₂, O, S, SO, SO₂, amino, amides, carbamates, ureas, or thiocarbonyl derivatives thereof, optionally substituted with an alkyl, alkenyl, or alkynyl group; n is from 1 to 5; X is a bond, an optionally substituted methylene or ethylene, an amino, O or S; Q is C(O), C(S), or SO₂; m is from 0 to 6; R⁴ is OH, =O (keto), NH₂, or alkylamino, including esters, amides, and salts thereof; and W is C(O), C(S), S(O), or SO₂. Optionally, R⁵ and R⁶, together with the N-W bond of formula (I), comprise a macrocyclic ring.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

6. The assay of claim 2, wherein said infectious microorganism is a malarial parasite.

7. The assay of claim 6, wherein said malarial parasite is a plasmodium species.
5

8. The assay of claim 2, wherein said infectious microorganism is a bacterium.

10 9. The assay of claim 1, wherein said predecessor is a cancer cell.

10. The assay of claim 9, wherein said cancer replicating biological entity is a rapidly growing tumor
15 cell.

11. The assay of any one of claims 1-10, wherein said biochemical target of said predecessor is an enzyme and said compound inhibits said enzyme of said
20 predecessor.

12. The assay of any one of claims 3-5, wherein said biochemical target of said predecessor is a viral protease, a viral reverse transcriptase, a viral
25 polymerase, a viral enzyme, or a viral protein.

13. The assay of claim 6 or 7, wherein said biochemical target of said malarial parasite is a plasmepsin, a plasmodial enzyme, or a protein.

36. The method of claim 35, wherein $K_{inh-mut}$, $K_{inh-pred}$, $k_{cat-mut}$, $k_{cat-pred}$, K_{M-mut} , and K_{M-pred} are each measured.

5 37. The method of claim 35 or 36, wherein K_{inh} is K_i .

38. The method of claim 35 or 36, wherein K_{inh} is K_d .

10 39. The assay of claim 1, wherein said predecessor
is a wild-type HIV strain and said mutant has at least
one mutation in the biochemical target thereof.

15 40. The method of claim 20, wherein said
replicating disease-causing replicating biological entity
is a wild-type HIV strain and said mutant has at least
one mutation in the biochemical target thereof.

20 41. The assay of claim 1, wherein said predecessor
has at least one mutation in the biochemical target
thereof, and said mutant has at least two mutations in
the biochemical target thereof.

25 42. The method of claim 20, wherein said
replicating disease-causing replicating biological entity
has at least one mutation in the biochemical target
thereof, and said mutant has at least two mutations in
the biochemical target thereof.

30 43. The method of claim 39 or 40, wherein said
mutant has at least one active site mutation.



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 493/04, 491/04, 495/04, A61K 31/34, C12Q 1/37, A61K 31/445		A3	(11) International Publication Number: WO 99/67417 (43) International Publication Date: 29 December 1999 (29.12.99)
<p>(21) International Application Number: PCT/US99/14119</p> <p>(22) International Filing Date: 23 June 1999 (23.06.99)</p> <p>(30) Priority Data: 60/090,393 23 June 1998 (23.06.98) US</p> <p>(71) Applicant (for all designated States except US): THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES [US/US]; National Institutes of Health, Office of Technology Transfer, Suite 325, 6011 Executive Boulevard, Rockville, MD 20852 (US).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): ERICKSON, John, W. [US/US]; 5406 Jefferson Boulevard, Frederick, MD 21703 (US). GULNIK, Sergei, V. [US/US]; 8004 Meadowview Drive, Frederick, MD 21702 (US).</p> <p>(74) Agents: GAGALA, Bruce, M. et al.; Leydig, Voit & Mayer, Ltd., Suite 4900, Two Prudential Plaza, 180 North Stetson, Chicago, IL 60601-6780 (US).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i></p> <p>(88) Date of publication of the international search report: 28 September 2000 (28.09.00)</p>	

(54) Title: FITNESS ASSAY AND ASSOCIATED METHODS

(57) Abstract

The present invention provides an assay for determining the biochemical fitness of a biochemical species in a mutant replicating biological entity relative to its predecessor. The present invention further provides a continuous fluorogenic assay for measuring the anti-HIV protease activity of protease inhibitor. The present invention also provides a method of administering a therapeutic compound that reduces the chances of the emergence of drug resistance in therapy.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERNATIONAL SEARCH REPORT

Inte. onal Application No
PCT/US 99/14119

A. CLASSIFICATION OF SUBJECT MATTER					
IPC 6	C07D493/04	C07D491/04	C07D495/04	A61K31/34	C12Q1/37
	A61K31/445				

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07D C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 766 842 A (HEEFNER DONALD L ET AL.) 16 June 1998 (1998-06-16) column 1, line 12 - line 40; claims 1,20 ---	1,5,12
X	KLABE, RONALD M. ET AL.: ""Resistance to HIV Protease Inhibitors: A Comparison of enzyme Inhibition and antiviral Potency"" BIOCHEMISTRY, vol. 37, no. 24, 1998, pages 8735-8742, XP002126126 Abstract --- -/-	1,5,12

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

6 June 2000

13. 6. 00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Kyriakakou, G

INTERNATIONAL SEARCH REPORT

Inte	onal Application No
PCT/US 99/14119	

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BORMAN, ANDREW M. ET AL: "Resistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug" J. GEN. VIROL., vol. 77, no. 3, 1996, pages 419-426, XP002126127 abstract ---	1,5,12
X	MARTINEZ-PICADO, JAVIER ET AL: "Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1" J. VIROL., vol. 73, no. 5, 1999, pages 3744-3752, XP002126128 abstract ---	1,5,12
A	WO 90 09191 A (SCHRAMM WOLFGANG; SCHRAMM HANS) 23 August 1990 (1990-08-23) the whole document ---	46
A	GB 2 276 621 A (MERCK & CO INC.) 5 October 1994 (1994-10-05) the whole document ---	46
A	WO 97 19055 A (NOVARTIS AG) 29 May 1997 (1997-05-29) page 1 -page 14 ---	47-62
A	WO 96 28463 A (G. D. DEARLE & CO.) 19 September 1996 (1996-09-19) page 4 -page 14, line 12 page 145 -page 189 ---	47-62
A	WO 95 06030 A (G. D. SEARLE & CO.) 2 March 1995 (1995-03-02) page 4 -page 18, paragraph 21 page 192 -page 212 ---	47-62
A	WO 94 14793 A (G. D. SEARLE & CO.) 7 July 1994 (1994-07-07) page 3, line 10 -page 13 ---	47-62
A	US 5 753 660 A (JAMES A. SIKORSKI ET AL.) 19 May 1998 (1998-05-19) the whole document ---	47-62
A	US 5 728 718 A (RAMNARAYAN S. RANDAD ET AL.) 17 March 1998 (1998-03-17) cited in the application the whole document ---	47-62
	-/-	

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 99/14119

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 723 490 A (ROGER D. TUNG) 3 March 1998 (1998-03-03) the whole document ---	47-62
A	US 5 705 500 A (DANIEL P. GETMAN ET AL.) 6 January 1998 (1998-01-06) the whole document ---	47-62
A	US 5 703 076 A (JOHN J. TALLEY) 30 December 1997 (1997-12-30) cited in the application the whole document ---	47-62
A	US 5 502 060 A (WAYNE J. THOMPSON) 26 March 1996 (1996-03-26) cited in the application the whole document -----	47-62

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 99/14119

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. Claims Nos.: 1-45 because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 99 14119

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-62

1. Claims: 1-46

Assays for determining evolutionary response of a viral protease to a protease inhibitor and methods of administering compounds identified using this assay, and afluorogenic assay for measuring anti-Hiv protease activity of a protease inhibitor.

2. Claims: 47-62

Method of preventing the development of drug resistance in an HIV infected mammal by administering compounds that inhibit development of drug-resistance.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 99 A4119

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 47-62 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Further defect(s) under Article 17(2)(a):

Claims Nos.: 20-45

Rule 39.1(iv) PCT- Method of treatment of the human or animal body by therapy

Continuation of Box I.2

Claims Nos.: 1-45

The claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Present claims 1-45 relate to a large number of possible assays. In fact, the claims contain so many options, variables, that a lack of clarity and conciseness within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search of the claims impossible. Consequently, the search has been carried out for those parts of the application which do appear to be clear (and/or concise), namely for an assay for determination of the activity of a viral protease of a mutant HIV-1 or HIV-2 in relation to its predecessor comprising obtaining a predecessor, determining the activity of the protease of said predecessor in the presence of a protease inhibitor, determining the activity of said protease inhibitor and comparing the two protease activities. (i.e. the first subject-matter of claim 12 when referring back to claims 1 via claim 5).

The description does not provide a proper support within the meaning of Article 5 and 6 PCT for any other embodiment covered by claims 1-45.

Moreover claims 20-45 refer to therapeutic compounds which are not characterised by any technical feature which would allow the formulation of a search for these claims or which would allow a meaningful comparison with methods of the state of the art.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/US 99/14119

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
US 5766842 A	16-06-1998	AU AU AU CA EP JP WO US	1953199 A 699561 B 3635295 A 2199805 A 0781351 A 10506272 T 9608580 A 6063562 A	20-05-1999 10-12-1998 29-03-1996 21-03-1996 02-07-1997 23-06-1998 21-03-1996 16-05-2000
WO 9009191 A	23-08-1990	AT DE EP ES JP US	131066 T 59009945 D 0409962 A 2084691 T 4503214 T 5674979 A	15-12-1995 18-01-1996 30-01-1991 16-05-1996 11-06-1992 07-10-1997
GB 2276621 A	05-10-1994	US	5436131 A	25-07-1995
WO 9719055 A	29-05-1997	AU CA EP JP	7623796 A 2237016 A 0876336 A 11514996 T	11-06-1997 29-05-1997 11-11-1998 21-12-1999
WO 9628463 A	19-09-1996	US AU AU BR CA CN CZ EP HU NO NZ PL SK US US	5756533 A 705268 B 5029496 A 9607638 A 2215061 A 1186499 A 9702824 A 0813542 A 9801562 A 974148 A 303861 A 322784 A 122497 A 5965601 A 5968970 A	26-05-1998 20-05-1999 02-10-1996 26-05-1998 19-09-1996 01-07-1998 18-02-1998 29-12-1997 30-11-1998 27-10-1997 25-02-1999 16-02-1998 04-03-1998 12-10-1999 19-10-1999
WO 9506030 A	02-03-1995	US US AT AU DE DE EP ES GR US US US US	5843946 A 6060476 A 174587 T 7669794 A 69415326 D 69415326 T 0715618 A 2127938 T 3029378 T 5830897 A 5786483 A 5744481 A 5968942 A	01-12-1998 09-05-2000 15-01-1999 21-03-1995 28-01-1999 02-06-1999 12-06-1996 01-05-1999 28-05-1999 03-11-1998 28-07-1998 28-04-1998 19-10-1999
WO 9414793 A	07-07-1994	US AT AU CA DE	5514801 A 148113 T 5736494 A 2153069 A 69307738 D	07-05-1996 15-02-1997 19-07-1994 07-07-1994 06-03-1997

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/US 99/14119

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9414793	A	EP	0677048 A	18-10-1995
		JP	8504815 T	28-05-1996
		US	5849784 A	15-12-1998
US 5753660	A	19-05-1998	AU 7722296 A	05-06-1997
			CA 2236236 A	22-05-1997
			EP 0861249 A	02-09-1998
			WO 9718205 A	22-05-1997
US 5728718	A	17-03-1998	AU 698252 B	29-10-1998
			AU 4378696 A	10-07-1996
			CA 2206787 A	27-06-1996
			EP 0801640 A	22-10-1997
			JP 10504838 T	12-05-1998
			US 5925780 A	20-07-1999
			WO 9619437 A	27-06-1996
US 5723490	A	03-03-1998	US 5783701 A	21-07-1998
			US 5585397 A	17-12-1996
			AU 706732 B	24-06-1999
			AU 5559696 A	07-11-1996
			BG 102048 A	31-08-1998
			BR 9608032 A	12-01-1999
			CA 2217737 A	24-10-1996
			CN 1181755 A	13-05-1998
			CZ 9703293 A	18-03-1998
			EP 0846110 A	10-06-1998
			HU 9801877 A	28-09-1999
			JP 10509739 T	22-09-1998
			NO 974722 A	13-10-1997
			PL 322877 A	02-03-1998
			SK 143197 A	08-04-1998
			WO 9633184 A	24-10-1996
			US 5977137 A	02-11-1999
			US 5856353 A	05-01-1999
			AP 390 A	02-08-1995
			AT 178598 T	15-04-1999
			AU 691160 B	14-05-1998
			AU 4852093 A	29-03-1994
			BG 62488 B	30-12-1999
			BG 99540 A	30-11-1995
			BR 1100824 A	31-08-1999
			CA 2143208 A	17-03-1994
			CN 1087347 A	01-06-1994
			CZ 9500587 A	13-12-1995
			DE 69324369 D	12-05-1999
			DE 69324369 T	26-08-1999
			EP 0659181 A	28-06-1995
			EP 0885887 A	23-12-1998
			ES 2131589 T	01-08-1999
			FI 951059 A	18-04-1995
			GR 3030719 T	30-11-1999
			HU 71892 A	28-02-1996
			JP 3012002 B	21-02-2000
			JP 8501299 T	13-02-1996
			LT 917 A, B	25-11-1994
			NO 950876 A	08-05-1995
			NZ 256238 A	24-04-1997

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/US 99/14119

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
US 5723490	A	NZ	314376 A	28-10-1998
		PL	307858 A	26-06-1995
		SG	43862 A	14-11-1997
		SK	29395 A	13-09-1995
		WO	9405639 A	17-03-1994

US 5705500	A	06-01-1998	AU 711098 B	07-10-1999
			AU 6695196 A	02-10-1996
			BR 9607450 A	30-06-1998
			CA 2215066 A	19-09-1996
			CN 1183767 A	03-06-1998
			CZ 9702822 A	18-02-1998
			EP 0813519 A	29-12-1997
			HU 9800294 A	28-07-1998
			JP 11503414 T	26-03-1999
			NO 974146 A	07-11-1997
			NZ 306026 A	28-01-1999
			PL 322169 A	19-01-1998
			SK 122397 A	04-02-1998
			WO 9628418 A	19-09-1996
			US 5985870 A	16-11-1999

US 5703076	A	30-12-1997	US 5475027 A	12-12-1995
			AT 155779 T	15-08-1997
			AU 662114 B	24-08-1995
			AU 9085191 A	11-06-1992
			DE 69126987 D	04-09-1997
			DE 69126987 T	05-03-1998
			DK 554400 T	16-02-1998
			EP 0554400 A	11-08-1993
			ES 2059289 T	16-11-1994
			GR 3024586 T	31-12-1997
			JP 6502859 T	31-03-1994
			PT 99551 A	30-10-1992
			WO 9208698 A	29-05-1992
			AT 170169 T	15-09-1998
			AT 164839 T	15-04-1998
			AT 147378 T	15-01-1997
			AT 136888 T	15-05-1996
			AU 9053191 A	11-06-1992
			AU 661667 B	03-08-1995
			AU 9092591 A	11-06-1992
			AU 9125191 A	11-06-1992
			AU 662309 B	31-08-1995
			AU 9133291 A	11-06-1992
			CA 2096407 A	20-05-1992
			CA 2096409 A	20-05-1992
			CA 2096525 A	20-05-1992
			CA 2096528 A	20-05-1992
			DE 69118907 D	23-05-1996
			DE 69124110 D	20-02-1997
			DE 69129235 D	14-05-1998
			DE 69129235 T	12-11-1998
			DE 69130070 D	01-10-1998
			DE 69130070 T	29-04-1999
			DK 558630 T	11-05-1998
			DK 558657 T	07-07-1997
			DK 558673 T	29-07-1996

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No	
PCT/US 99/14119	

Patent document cited in search report	Publication date	Patent family member(s)		Publication date	
US 5703076	A	EP	0558603 A	08-09-1993	
		EP	0558630 A	08-09-1993	
		EP	0558657 A	08-09-1993	
		EP	0558673 A	08-09-1993	
		EP	0735019 A	02-10-1996	
		EP	0731088 A	11-09-1996	
		EP	0813867 A	29-12-1997	
		EP	0815856 A	07-01-1998	
		EP	0813868 A	29-12-1997	
		ES	2059293 T	16-11-1994	
		ES	2059295 T	16-11-1994	
		ES	2059294 T	16-11-1994	
		ES	2059296 T	16-11-1994	
<hr/>					
US 5502060	A	26-03-1996	AT	175412 T	15-01-1999
			AU	649170 B	12-05-1994
			AU	2725392 A	29-04-1993
			CA	2081134 A	24-04-1993
			DE	69228106 D	18-02-1999
			DE	69228106 T	15-07-1999
			EP	0539192 A	28-04-1993
			ES	2125251 T	01-03-1999
			JP	1948611 C	10-07-1995
			JP	5239031 A	17-09-1993
			JP	6078314 B	05-10-1994
			NZ	244773 A	26-10-1994
			WO	9308184 A	29-04-1993
			ZA	9208164 A	03-05-1993